Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 7/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609961 | 0.77 | MEN1 (0.38) | KDM4EALDH1A1GAAMAPTEGFR | |
| SCHEMBL7604621 | 0.76 | MEN1 (0.39) | KDM4EALDH1A1GAAMAPTEGFR | |
| SCHEMBL7612716 | 0.75 | KDM4E (0.50) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL7611712 | 0.75 | TDP1 (0.40) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL7604578 | 0.75 | MEN1 (0.36) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL7608625 | 0.73 | ALDH1A1 (0.50) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL2527739 | 0.73 | KDM4E (0.57) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL2087168 | 0.70 | HPGD (0.61) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL10523769 | 0.69 | KDM4E (0.56) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL17102815 | 0.69 | KDM4E (0.59) | KDM4EALDH1A1GAAMAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| JP-2002514160-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | claimed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |